The general mood among these heavyweight investors is divided, with 70% leaning bullish and 20% bearish. Among these notable ...

The company's vice president and general manager of U.S. business operations explains how Amgen is going to deliver on its ...

We know that weight loss drugs have been big winners for the companies that produce them. And now, biotech stock Amgen (AMGN) ...

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Investment analysts at William Blair issued their Q4 2026 earnings per share estimates for Amgen in a research report issued ...

A key part of Amgen’s strategy was to broaden the indications for those drugs it already owned, with Epogen successfully obtaining indications for anaemia in cancer patients, Enbrel broadening ...

Research analysts at William Blair issued their Q1 2026 EPS estimates for shares of Amgen in a research note issued on ...

Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Amgen's whale ...

Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer ...

Enbrel sales beat the Zacks Consensus Estimate of $864.0 million as well as our estimate of $874.5 million. Going forward, Amgen expects volumes to be flat for Enbrel, while net selling price is ...